Skin & Collagen

Research compounds studied for collagen synthesis, skin elasticity, wound healing, and photoprotection. Many available topically - no injection required for entry-level use.

Most researched for Skin & Collagen

GHK-Cu

The most extensively researched skin peptide with decades of published data. A naturally occurring copper-binding tripeptide that activates collagen and elastin gene expression. Unique because it is effective both topically (as a serum) and systemically (injected). Research shows activation of over 4,000 genes related to tissue remodeling and anti-aging. The most accessible entry point with the strongest evidence base.

Acetyl Tetrapeptide-9

aka Collalift, Dermican

PopularCosmetic ingredient

Acetyl Tetrapeptide-9 is a synthetic topical cosmetic peptide marketed as Collalift. In laboratory testing it has been reported to stimulate synthesis of lumican, a small proteoglycan that helps organize collagen fibers in the dermis. It is formulated into anti-aging and firming skincare products. Published evidence rests largely on laboratory and manufacturer studies rather than independent clinical trials.

How it works: It is reported to stimulate lumican, a collagen-organizing proteoglycan, supporting dermal matrix structure in laboratory studies.

Anti-aging serums; firming creams; eye creams; dermal density support

Research dose

3-6 % (topical), 1–2×/day

Real-world (reported)

3–6% in serum/cream. Combine with Matrixyl.

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL] Used by sophisticated formulators targeting skin structural improvement beyond just collagen quantity.

Onset
Firmness 4–8 wks
Half-life
Not established
Storage
Dry: Room temp or fridge
Rare side effects
No serious adverse effects
Contraindications
Known sensitivity
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
Matrixyl: collagen synthesis complement (synthesis + organization). Hexapeptide-10: DEJ support.
Secondary uses
ECM remodeling; skin structure improvement
Legal status
US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
Typical price
$10–$50 / ingredient
Research evidence
Cell or lab studies only
Chemical data
CAS 928006-50-2 · C22H33N7O9 · 539.5

Collagen Peptides

aka Hydrolyzed collagen, collagen hydrolysate, Peptan

PopularInvestigational

Collagen peptides are hydrolyzed collagen fragments sold as an oral supplement under names such as Peptan. Ingested peptides are absorbed and may act as signaling molecules that stimulate fibroblast activity and matrix production. Randomized trials and meta-analyses report improvements in skin hydration and elasticity, although study quality and industry funding vary considerably.

How it works: Hydrolyzed collagen fragments are absorbed and may signal fibroblasts to increase collagen and extracellular matrix synthesis.

Skin hydration; skin elasticity; nail and hair support; joint and bone research

Research dose

5-15 g, Once daily

Real-world (reported)

10g/day oral. Take with 200mg Vitamin C.

Administration

Oral

Timing

Any time

Cycle length

12 wks (skin); 24 wks (joints)

Real-world figures are community-reported, not medical advice.

Common side effects: Mild gastrointestinal discomfort; fullness; aftertaste

Community take: [ANECDOTAL] Well-established supplement with good RCT base. 10g/day minimum; bovine or marine; 12+ weeks. Vitamin C co-administration important.

Onset
Skin 4–8 wks; joint 12–24 wks; bone months
Half-life
Not established
Storage
Dry: Room temperature; dry
Reconstitution
N/A (food/supplement)
Rare side effects
No serious effects; long safety record as food supplement
Contraindications
Animal-derived hypersensitivity (bovine/marine/porcine)
Drug interactions
No significant interactions
Recommended bloodwork
Optional PINP/P1NP (bone collagen marker)
Stacks well with
GHK-Cu topical: systemic (oral) + local (topical) collagen synergy. Vitamin C: essential co-factor.
Secondary uses
Bone density; muscle mass (adjunct); hair and nails; wound healing
Legal status
US: Dietary supplement (FDA 21 CFR) · UK: Dietary supplement / food ingredient · Canada: NHP (Natural Health Product) · Australia: TGA-listed therapeutic / food · EU: Food supplement; member state level
Typical price
$20–$60 / month supply
Research evidence
Human trials - early or small

Leuphasyl

aka Pentapeptide-18

PopularCosmetic ingredient

Leuphasyl is the trade name for pentapeptide-18, a synthetic peptide related to the natural opioid peptide leu-enkephalin. It is used in topical cosmetic products, sometimes alongside other peptides, and is marketed to soften the appearance of expression lines. Its cosmetic activity is supported mainly by manufacturer and laboratory data. It is regulated as a cosmetic ingredient.

How it works: It acts as an enkephalin-like ligand at neuronal receptors and is proposed to modulate the signaling that drives muscle contraction.

Expression lines; forehead wrinkles; combination formulations; cosmetic anti-aging

Research dose

2-5 % (topical), 1–2×/day

Real-world (reported)

3–5% serum; combine with Argireline.

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL] Less well known than Argireline but additive. Formulators combine 3–5% each.

Onset
4–8 wks expression wrinkle reduction
Half-life
Not established
Storage
Dry: Room temp or fridge
Rare side effects
No serious adverse effects
Contraindications
Known sensitivity
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
Argireline: additive effect demonstrated. Syn-Ake: NMJ modulator complement.
Secondary uses
Crow's feet; frown lines; forehead
Legal status
US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
Typical price
$10–$40 / ingredient
Research evidence
Minimal published research
Chemical data
CAS 64963-01-5 · C29H39N5O7 · 569.6

Palmitoyl Tripeptide-1

aka Pal-GHK, Biopeptide EL, Biopeptide CL

PopularCosmetic ingredient

Palmitoyl Tripeptide-1 is a synthetic lipopeptide consisting of a glycine-histidine-lysine sequence linked to a palmitic acid chain that improves skin penetration. It is used in topical cosmetic products, often within combination formulations, and is marketed to support the appearance of firmer skin. In laboratory studies it has been reported to stimulate fibroblast activity and matrix components. It is regulated as a cosmetic ingredient.

How it works: It is proposed to signal dermal fibroblasts to increase production of collagen and glycosaminoglycans.

Skin firmness; fine line appearance; combination formulations; cosmetic anti-aging

Research dose

2-8 % (topical), 1–2×/day

Real-world (reported)

3–8% in serum/cream daily.

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL] Classic collagen peptide. Frequently combined with Matrixyl 3000 in commercial formulations.

Onset
Collagen changes 4–12 wks; firmness 8 wks
Half-life
Not established
Storage
Dry: Room temp or fridge
Rare side effects
No serious adverse effects
Contraindications
Known sensitivity
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
Palmitoyl Pentapeptide-4 (Matrixyl): additive collagen stimulation. GHK-Cu injectable: injectable complement.
Secondary uses
Fibronectin; skin texture
Legal status
US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
Typical price
$5–$40 / product
Research evidence
Cell or lab studies only
Chemical data
CAS 147732-56-7 · C30H54N6O5 · 578.8

Syn-Ake

aka Dipeptide Diaminobutyroyl Benzylamide Diacetate

PopularCosmetic ingredient

Syn-Ake is the trade name for a synthetic peptide modeled on waglerin-1, a component of temple viper venom. It is used in topical cosmetic products marketed to relax facial muscle movement and soften the look of expression lines. Reported activity comes largely from laboratory and manufacturer data rather than independent peer-reviewed clinical trials. It is regulated as a cosmetic ingredient.

How it works: It is designed to act as an antagonist at muscle nicotinic acetylcholine receptors, reducing muscle contraction linked to expression lines.

Expression lines; forehead wrinkles; facial muscle relaxation; cosmetic anti-aging

Research dose

2-4 % (topical), 1–2×/day

Real-world (reported)

2–4% serum on expression lines 1–2×/day.

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL] 2–4% noticeable wrinkle reduction. Different mechanism from Argireline so additive when combined.

Onset
Expression wrinkle reduction 4–8 wks
Half-life
Not established
Storage
Dry: Room temp or fridge
Reconstitution
N/A (pre-formulated)
Rare side effects
No serious adverse effects at cosmetic concentrations
Contraindications
Known sensitivity
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
Argireline: complementary SNARE mechanism (additive). Snap-8: additional SNARE complement.
Secondary uses
Skin smoothing; anti-aging
Legal status
US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
Typical price
$10–$60 / cosmetic product
Research evidence
Minimal published research
Chemical data
CAS 823202-99-9 · C23H37N5O7 · 495.6

Hexapeptide-10

aka Serilesine, SIKVAV

PopularCosmetic ingredient

Hexapeptide-10, sold as Serilesine, is a synthetic cosmetic peptide that mimics an adhesion fragment of the laminin protein. In laboratory studies it promotes skin cell adhesion and proliferation and supports the junction between the epidermis and dermis. It is used in topical firming and anti-aging formulations. Independent clinical evidence in cosmetics is limited.

How it works: It is a laminin-derived peptide that promotes keratinocyte and fibroblast adhesion and reinforces the dermo-epidermal junction.

Firming skincare; anti-aging serums; skin density; dermo-epidermal support

Research dose

2-5 % (topical), 1–2×/day

Real-world (reported)

3–5% serum. Combine with Matrixyl.

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL] Less mainstream than Matrixyl but valued for DEJ support in premium formulations.

Onset
Firmness 4–12 wks
Half-life
Not established
Storage
Dry: Room temp or fridge
Rare side effects
No serious adverse effects
Contraindications
Known sensitivity
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
Matrixyl: collagen complement. GHK-Cu: comprehensive anti-aging skin stack.
Secondary uses
Hair follicle anchoring (niche)
Legal status
US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: Legal OTC cosmetic · EU: Legal OTC cosmetic
Typical price
$10–$50 / ingredient
Research evidence
Cell or lab studies only
Chemical data
CAS 146439-94-3 · C28H53N7O8 · 615.8

Key risk: Laboratory findings that its core sequence can promote blood vessel growth and tumor progression warrant caution, though the relevance to topical use is not established.

Matrixyl

aka Palmitoyl Pentapeptide-4, Pal-KTTKS, Palmitoyl Pentapeptide-3

PopularApproved

Matrixyl is the trade name for palmitoyl pentapeptide-4, a synthetic lipopeptide that joins a fragment of type I procollagen to a palmitic acid chain that aids skin penetration. It is used in topical cosmetic products marketed for the appearance of fine lines and photoaged skin. A small controlled clinical study reported improved wrinkle appearance and good skin tolerability. It is regulated as a cosmetic ingredient rather than a drug.

How it works: It acts as a matrikine signal proposed to prompt dermal fibroblasts to increase synthesis of collagen and other matrix proteins.

Fine line appearance; photoaged skin; skin firmness; cosmetic anti-aging

Research dose

2-8 % (topical), 1–2×/day

Real-world (reported)

2–8% in serum or cream applied daily. Often combined with GHK-Cu and/or Argireline.

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL – skincare community] One of most researched cosmetic peptides. Widely used in anti-aging serums. Clinical studies demonstrate measurable collagen increase.

Onset
Collagen changes 4–12 wks; skin firmness 8 wks
Half-life
Not established
Storage
Dry: Room temp or fridge; follow label
Rare side effects
No serious adverse effects documented
Contraindications
Known ingredient sensitivity; Known hypersensitivity to palmitoyl pentapeptide-4 or related cosmetic peptide i; Use on broken; wounded; or severely compromised skin should be avoided unless sp; No significant interactions with other topical skincare ingredients have been id
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
GHK-Cu: additive collagen stimulation. Palmitoyl Tripeptide-1: complementary collagen pathway.
Secondary uses
ECM remodeling; skin hydration; anti-aging
Legal status
Approved
Typical price
$5–$40 / product
Research evidence
Human trials - early or small
Indications
Anti-aging skincare (wrinkle and fine line reduction); Collagen stimulation in photoaged skin; Cosmetic formulation active ingredient
Chemical data
CAS 214047-00-4 · C39H75N7O10 · 802.05 Da
Amino acids
41 aa

Snap-8

aka Acetyl Octapeptide-3, Acetyl Glutamyl Heptapeptide-1

PopularApproved

Snap-8, known by the cosmetic ingredient names Acetyl Octapeptide-3 and Acetyl Glutamyl Heptapeptide-1, is a topical peptide used in anti-wrinkle skincare. It is a fragment that mimics part of the SNAP-25 protein and is proposed to interfere with the SNARE complex that drives neurotransmitter release, so facial muscle contraction is reduced. It is studied mainly for softening expression lines on the forehead and around the eyes.

How it works: It mimics part of the SNAP-25 protein and interferes with the SNARE complex, reducing the neurotransmitter release that triggers muscle contraction.

Expression line reduction; anti-wrinkle skincare; topical cosmetic formulation

Research dose

3-8 % (topical), 1–2×/day

Real-world (reported)

3–8% in serum formulation. Used alongside Argireline for additive effect.

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL – skincare community] Preferred over Argireline by some formulators for potentially stronger effect at lower concentration. DIY cosmetics use common.

Onset
Expression wrinkle reduction 4–8 wks
Half-life
Not established
Storage
Dry: Room temp or fridge
Reconstitution
N/A (pre-formulated)
Rare side effects
No serious adverse effects
Contraindications
Known ingredient sensitivity; Known hypersensitivity to SNAP-8 or related peptide ingredients; Active skin infections or open wounds at application site; Severe inflammatory skin conditions at application siteFrequency distribution of; No significant drug interactions reported for topical SNAP-8
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
GHK-Cu: collagen synergy. Argireline: similar mechanism (often combined).
Secondary uses
Forehead lines; eye wrinkles; facial rejuvenation
Legal status
Preclinical Research
Typical price
$10–$40 / raw ingredient; $20–$60 / commercial serum
Research evidence
Minimal published research
Indications
Anti-wrinkle and anti-aging cosmeceutical research; Topical neuromuscular junction modulation studies; SNARE complex inhibition research; Cosmetic peptide formulation development
Chemical data
CAS 868844-74-0 · C41H70N16O16S · 1075.16 Da
Amino acids
215 aa

Argireline

aka Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

PopularCosmetic ingredient

Argireline is the trade name for acetyl hexapeptide, a synthetic peptide whose sequence corresponds to the end of the SNAP-25 protein involved in neurotransmitter release. It is used in topical cosmetic products intended to soften the appearance of expression lines. A 2002 study reported reduced wrinkle depth with a topical formulation, although independent clinical evidence remains limited. It is regulated as a cosmetic ingredient.

How it works: It mimics the SNAP-25 protein terminus and is proposed to interfere with SNARE complex formation, reducing muscle contraction.

Expression lines; forehead wrinkles; crow's feet appearance; cosmetic anti-aging

Research dose

5-10 % (topical), 1–2×/day (topical serum/cream)

Real-world (reported)

5–10% serum applied to expression lines 1–2×/day. Leave 20 min before other skincare.

Administration

Topical (serum, cream, eye cream)

Timing

Morning and/or evening

Cycle length

Ongoing (cosmetic use)

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL – skincare community] Very popular in DIY skincare. At 5–10%, meaningful wrinkle reduction reported. 'Budget Botox.' Must stay on skin long enough to penetrate.

Onset
Expression wrinkle reduction 4–8 wks
Half-life
Not established
Storage
Dry: Room temperature or fridge; follow product label
Reconstitution
N/A (pre-formulated cosmetic)
Rare side effects
No serious adverse effects documented at cosmetic concentrations
Contraindications
Known sensitivity to any ingredient; Known hypersensitivity to acetyl hexapeptide-8 or any formulation components; Should not be used as a substitute for medical treatment of neuromuscular disord; No significant interactions with other topical skincare ingredients. Compatible
Drug interactions
No significant interactions at cosmetic use
Recommended bloodwork
None required for cosmetic topical use
Stacks well with
GHK-Cu: synergistic collagen + wrinkle combo. Snap-8: similar mechanism, additive.
Secondary uses
Skin smoothing; anti-aging
Legal status
Preclinical Research
Typical price
$5–$30 / cosmetic serum
Research evidence
Human trials - early or small
Indications
Dynamic wrinkle reduction (forehead lines, crow's feet, frown lines); Anti-aging cosmetic formulations; Non-invasive alternative to botulinum toxin injections
Chemical data
CAS 616204-22-9 · C34H60N14O12S · 889 Da
Amino acids
46 aa

OS-01

aka Peptide 14, Decapeptide-52, OneSkin peptide

PopularPreclinical

OS-01 is a synthetic ten amino acid peptide developed by OneSkin and assigned the cosmetic name Decapeptide-52. It is described as a topical senotherapeutic intended to reduce markers of cellular senescence in skin. A twelve-week split-face, vehicle-controlled study reported reduced water loss and improved wrinkle appearance and texture. It is marketed as a cosmetic rather than a drug, and independent replication remains limited.

How it works: It is proposed to act as a senotherapeutic, reducing accumulation of senescent cells and their inflammatory secretions in skin.

Skin rejuvenation; wrinkle reduction; barrier support; senescence reduction

Administration

Topical

Timing

Apply to clean skin before moisturizer; morning and evening

Cycle length

Ongoing (minimum 8-12 weeks for results)Step-wise Titration

Common side effects: Not established

Half-life
Not established
Contraindications
Known allergy to any component of the OneSkin formulation; Open wounds or severely damaged skin (not studied in this population)Frequency d; No drug interactions have been formally studied for topical OS-01 formulations👥
Legal status
Preclinical Research
Research evidence
Human trials - early or small
Indications
Topical skin rejuvenation (cosmetic product); Skin barrier function improvement; Reduction of visible signs of skin aging
Amino acids
10 aa

GHK-Cu Topical Serum

PopularCosmetic ingredient

This entry describes glycyl-L-histidyl-L-lysine copper as a topical serum presentation. It is the same molecule as the existing GHK-Cu row and differs only by presentation. GHK-Cu is a copper-binding tripeptide studied for effects on collagen synthesis, matrix remodeling, and wound repair, used mainly as a topical cosmetic ingredient.

How it works: It carries copper into tissue and acts as a signaling molecule that modulates genes linked to matrix remodeling and repair.

Skin anti-aging; collagen support; wound healing research; hair research

Research dose

0.05-1 % (topical), 1–2×/day

Real-world (reported)

0.1–0.5% serum daily. Scalp 0.1% for hair. Do NOT use same session as Vitamin C (oxidation).

Administration

Topical

Timing

Morning and/or evening

Cycle length

Ongoing

Real-world figures are community-reported, not medical advice.

Common side effects: Local skin irritation; redness; itching

Community take: Preclinical research demonstrates synergistic benefit when GHK-Cu is combined with Torilis japonica extract at a 4:6 ratio, showing simultaneous anti-inflammatory, antioxidant, and regenerative effects with no cell viability compromise.

Onset
Skin 4–12 wks; scar months
Half-life
Not established
Storage
Dry: Fridge preferred; room temp ≤3 mo; light sensitive
Reconstitution
N/A (pre-formulated)
Rare side effects
No serious effects at cosmetic concentrations
Contraindications
Known copper allergy; Wilson's disease
Drug interactions
No cosmetic interactions
Recommended bloodwork
None required
Stacks well with
GHK-Cu injectable: same compound different route. Argireline: expression wrinkle complement. Matrixyl: collagen synergy.
Secondary uses
Antioxidant support, wound healing
Legal status
US: Legal OTC cosmetic · UK: Legal OTC cosmetic · Canada: Legal OTC cosmetic · Australia: TGA cosmetic listed; injectable regulated separately · EU: Legal OTC cosmetic
Typical price
$10–$60 / serum
Research evidence
Human trials - early or small

Afamelanotide

aka Scenesse, Melanotan I, NDP-MSH

ModerateApproved

Afamelanotide is a synthetic analog of alpha-melanocyte-stimulating hormone that activates the melanocortin-1 receptor to increase protective eumelanin pigment in the skin. Marketed as the implant Scenesse, it is FDA approved to increase pain-free light exposure in adults with erythropoietic protoporphyria. It has also been researched for other light-sensitivity and pigmentation conditions such as vitiligo.

How it works: It binds and activates the melanocortin-1 receptor, stimulating protective eumelanin pigment production in the skin.

Erythropoietic protoporphyria; skin photoprotection; pigmentation disorders; vitiligo research

Administration

SC

Timing

Administered by certified healthcare provider as a bioresorbable implant above the anterior supra-iliac crest. Typically 5-6 implants per year.

Cycle length

Seasonal (spring through fall)

Common side effects: Implant site reactions; nausea; oropharyngeal pain; cough; fatigue

Half-life
Approximately 30 minutes
Reconstitution
Sterile water
Contraindications
Known hypersensitivity to afamelanotide or any component of the implant; Patients should not have unexamined suspicious melanocytic lesions prior to impl; No clinically significant drug interactions have been identified. Afamelanotide; Afamelanotide does not replace the need for sun protection measures. Patients sh
Legal status
Approved
Research evidence
Approved - large human trials
Indications
Erythropoietic protoporphyria (EPP) photoprotection (FDA/EMA approved); Vitiligo repigmentation (Phase 3 investigational)
Chemical data
CAS 75921-69-6 · C78H111N21O19 · 1647 Da
Amino acids
260 aa

Key risk: Increased skin pigmentation may mask developing skin cancers, so periodic skin monitoring is recommended.

Melanotan II

aka MT-II, MT-2

ModeratePreclinical

Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone that non-selectively activates several melanocortin receptors, including MC1 and MC4. Through MC1 it darkens skin by stimulating melanin, and through MC4 it can influence sexual arousal and appetite. It is not approved for any human use and is sold only as an unregulated research chemical, and it is a different molecule from afamelanotide, which is Melanotan I.

How it works: It non-selectively activates melanocortin receptors, increasing skin melanin through MC1 and affecting sexual function through MC4.

Skin tanning; erectile function; appetite research; melanocortin studies

Research dose

250-1000 mcg, Daily (loading) then maintenance 2–3×/week

Real-world (reported)

Start low 250 mcg; build to 500–1000 mcg. Evening dose to sleep through nausea. UV exposure needed for tanning effect.

Administration

SubQ

Timing

Evening (nausea management)

Cycle length

Loading 1–2 wks; maintenance ongoing (with UV exposure for tanning)

Real-world figures are community-reported, not medical advice.

Common side effects: Facial flushing; nausea and vomiting; appetite loss; spontaneous erections; darkening of moles

Community take: [ANECDOTAL] Very popular for tanning. 'Barbie drug' in media. Community concern about mole changes — dermatology visits recommended. Libido effect strong.

Onset
Tanning 2–4 wks with UV; libido hours
Half-life
Not established in humans
Storage
Dry: Fridge 2–8°C; freeze long-term; protect from light · Reconstituted: Refrigerate; use within 28 days
Reconstitution
Add 2 mL BAC water to 10 mg vial = 5 mg/mL; 500 mcg dose = 10 IU
Rare side effects
Darkening/enlargement of moles (melanoma risk concern); melanoma case reports; prolonged erection; hypertension; hyperpigmentation of normal skin
Contraindications
Personal or family history of melanoma; active malignancy; pregnancy; cardiovascular disease; PT-141 preferred for pure sexual health (fewer pigmentation concerns); Uncontrolled hypertension or significant cardiovascular disease; History or risk of priapism; Pregnancy and lactation; Severe renal impairment
Drug interactions
Antihypertensives (additive BP effects); sexual function medications
Recommended bloodwork
Dermatology check (mole mapping) before and every 6 months; BP monitoring
Stacks well with
PT-141 (more selective; no tanning — choose one or the other based on goal).
Secondary uses
Appetite suppression; fat loss (secondary)
Legal status
Preclinical Research
Typical price
$25–$60 / 10 mg vial
Research evidence
Human trials - early or small
Indications
Melanogenesis and tanning research; Melanocortin receptor pharmacology studies; Sexual function research (led to development of PT-141); Appetite regulation and energy homeostasis studies
Chemical data
CAS 121062-08-6 · C50H69N15O9 · 1024.18 Da
Amino acids
243 aa

Key risk: It has been associated with new and darkening melanocytic moles and reported cases of melanoma.

Icotrokinra

aka Icotyde, JNJ-2113, JNJ-77242113

ModeratePhase 3

Icotrokinra is an orally administered peptide that selectively blocks the interleukin-23 receptor, interrupting a signaling pathway that drives the inflammation underlying plaque psoriasis. It is a once-daily pill and is notable as the first oral agent to target this receptor. The FDA approved it in March 2026 under the brand name Icotyde for adults and adolescents with moderate to severe plaque psoriasis.

How it works: It is a peptide antagonist that binds the interleukin-23 receptor, blocking IL-23 signaling that promotes inflammatory responses.

Plaque psoriasis; psoriatic disease; interleukin-23 mediated inflammation

Administration

Oral

Timing

Once-daily oral tablet; no specific timing relative to meals reported

Cycle length

OngoingStep-wise Titration

Common side effects: Headache; nausea; cough; fatigue; fungal infections

Half-life
Not established
Storage
Dry: Store at room temperature; protect from moisture and light
Contraindications
Known hypersensitivity to icotrokinra or any excipient; Active serious infections (consistent with immunomodulatory therapy guidelines)F; No clinically significant drug interactions have been identified in clinical tri; Live vaccines should be avoided during treatment, consistent with recomm
Legal status
Investigational
Research evidence
Approved - large human trials
Indications
Moderate-to-severe plaque psoriasis (adults and adolescents 12+); Scalp and genital psoriasis (high-impact sites); Ulcerative colitis (Phase 2b, under investigation)
Chemical data
CAS 2763602-16-8 · C90H120N20O22S2 · 1898.19 Da
Amino acids
160 aa

Key risk: No boxed warning applies; tuberculosis screening is advised before starting treatment.

Botulinum Toxin

aka Botox, OnabotulinumtoxinA, BoNT-A

AdvancedApproved

Botulinum toxin type A is a purified neurotoxin protein produced by Clostridium botulinum and marketed as Botox. It is FDA approved for a broad range of therapeutic uses, including chronic migraine, cervical dystonia, spasticity, overactive bladder, severe underarm sweating, and blepharospasm. It acts locally at the neuromuscular junction to inhibit acetylcholine release.

How it works: It cleaves SNARE proteins to inhibit acetylcholine release at the neuromuscular junction, producing local chemodenervation.

Chronic migraine; cervical dystonia; spasticity; overactive bladder; hyperhidrosis

Administration

IM

Timing

No specific time of day; administered in clinic by trained healthcare professional

Cycle length

Ongoing; repeated every 12 weeks as needed

Common side effects: Injection site pain or bruising; headache; neck pain; urinary tract infection; eyelid drooping

Half-life
Not established
Storage
Dry: Store unopened vials refrigerated at 2-8C (or frozen at or below -5C for some formulations). Reconstituted solution: store refrigerated and use within
Reconstitution
Sterile 0.9% salineUse within: 24 hours
Contraindications
Known hypersensitivity to botulinum toxin or any formulation component; Infection at the proposed injection site; Pre-existing neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome,; Pregnancy and breastfeeding (Category C; insufficient data)Frequency distributio
Legal status
Approved
Research evidence
Approved - large human trials
Indications
Chronic migraine prophylaxis; Cervical dystonia; Upper and lower limb spasticity; Blepharospasm; Cosmetic treatment of facial wrinkles; Axillary hyperhidrosis; Overactive bladder
Chemical data
CAS 93384-43-1 · Complex protein · 149000 Da
Amino acids
296 aa

Key risk: The toxin effect may spread from the injection site, and resulting swallowing and breathing difficulties can be life threatening, with reports of death.

Epitalon Oral

aka Oral Epitalon

AdvancedPreclinical

This entry is an oral presentation of Epitalon, the synthetic tetrapeptide Ala-Glu-Asp-Gly modeled on a pineal preparation. It is the same molecule as the existing Epitalon row and is not a separate compound. Epitalon is studied for reported effects on melatonin, telomerase activity, and aging markers, largely in animal models and small human studies. Oral peptide bioavailability is generally low.

How it works: It is reported to influence pineal and neuroendocrine signaling and telomerase activity in preclinical work.

Longevity research; telomere biology; aging studies

Research dose

20-30 mg, Daily (oral)

Real-world (reported)

20–30 mg oral daily ×10–20 consecutive days. 2 cycles/year.

Administration

Oral

Timing

Morning

Cycle length

10–20 day course; 2× per year

Real-world figures are community-reported, not medical advice.

Common side effects: Not established

Community take: [ANECDOTAL] Many longevity users prefer oral for convenience vs injectable. Debate: injectable may have superior bioavailability. Community divided.

Onset
Sleep effects 1–2 wks; biomarker changes months
Half-life
Not established
Storage
Dry: Room temperature; dry
Reconstitution
N/A (pre-formulated)
Rare side effects
Same theoretical concerns as injectable; less studied than injectable
Contraindications
Active malignancy (theoretical); pregnancy
Drug interactions
No significant interactions
Recommended bloodwork
Melatonin; telomere length (research context)
Stacks well with
Thymalin: immune complement. GHK-Cu: tissue repair longevity stack.
Secondary uses
Oral convenience vs injectable; lower bioavailability debated
Legal status
US: Research use only; PCAC July 2026 · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
Typical price
$30–$60 / pack
Research evidence
Human trials - early or small

Example stacks

Beginner

Skin & Collagen - Beginner

Topical GHK-Cu serum is the most accessible entry point - no injections, widely available, and decades of evidence behind it.

Primary
GHK-Cu topicalFew drops AM + PM - After cleansing, before moisturizer
  • • Apply to clean dry skin after cleansing
  • • Use AM and PM consistently
  • • Choose a serum with GHK-Cu listed as a primary active
Intermediate

Skin & Collagen - Intermediate

Systemic GHK-Cu via injection delivers peptide throughout the whole body. Combined with Epithalon it addresses skin aging from both structural and cellular angles.

Primary
GHK-Cu1 mg/day - Daily subcutaneous
Support
Epithalon5 mg/day - Before bed
  • • Rotate injection sites for daily GHK-Cu
  • • Take before and after photos at weeks 0, 4, 8, 12
  • • Combine systemic with topical GHK-Cu

Community outcome data

Collected from users researching this goal. Not a clinical database - for general reference only.

Share your experience

Your experience helps others research this goal. All submissions are anonymous.

Poor
Excellent

Ready to actually use this research?

FREE

Two tools that turn this research into something you can actually use - no signup needed.

For educational and research purposes only. Not medical advice. Always consult a qualified healthcare provider before using any research compound.